Use of novel wet age-related macular degeneration treatment given nod by FDAAccording to a report coming from NeoVista, Inc., the FDA has approved its “compassionate case” waiver for utilizing its novel wet age-related macular degeneration (AMD) treatment on a patient with an advanced form of this disease.

The procedure was performed by Dr. Carl Awh, President of Tennessee Retina, and an investigator in NeoVista’s ongoing Phase III study, CABERNET (CNV Secondary to AMD Treated with BEta RadiatioN Epiretinal Therapy).

Dr. Awh remarked that both he and his patient would now be accessible to a promising and new therapy for treating the case of severe wet AMD.

John N. Hendrick, President and CEO of NeoVista, said that it is extremely pleasing to note that the FDA has granted its approval to allow the use of a compassionate use waiver in this circumstance.